RxDoctor Payments Data

Fady Henein, MD

Psychiatry · Waycross, GANPI 1265788079

Payments from drug & device makers

$3,271in general payments, 2019–2025

Across 160 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$977
  • Alkermes, Inc.$597
  • Otsuka America Pharmaceutical, Inc.$559
  • Johnson & Johnson$335
  • E.r. Squibb & Sons, L.L.C.$239
  • Lundbeck LLC$223
  • plus $341 from 7 others

What the payments were for

  • Food & beverage$3,09094%
  • Education$1816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,271 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$123,779
Medicare patients
198
Services billed
1,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$21,577
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl49$19,171
Chlorpromazine Hcl13$4,356
Gabapentin130$3,539
Divalproex Sodium ErDivalproex Sodium20$2,671
Quetiapine Fumarate93$2,064
Aripiprazole46$1,872
Trazodone Hcl104$1,731
Atomoxetine Hcl11$1,700
Divalproex Sodium40$1,693
Hydroxyzine Pamoate69$1,378
Haloperidol19$1,179
Omeprazole74$1,043
Olanzapine40$1,041
Fluoxetine Hcl68$963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$559$21,57715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Waycross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →